Table 4 Univariable and multivariable Cox proportional hazard regression analyses of overall survival
Factor | Univariable analysis | P | Multivariable analysis | P | |
|---|---|---|---|---|---|
HR (95%CI) | HR (95% CI) | ||||
Gender | |||||
Male | Reference | ||||
Female | 1.376 (0.766–2.472) | 0.286 | |||
Age at diagnosis | |||||
< 30y | Reference | ||||
≥ 30 y | 1.450(0.839–2.507) | 0.183 | |||
Primary site | |||||
Extremity | Reference | ||||
Trunk | 1.105 (0.620–1.971) | 0.735 | |||
Tumor origin | |||||
Skeletal | Reference | ||||
Extraskeletal | 0.660 (0.346–1.261) | 0.209 | |||
Stage | |||||
Localized | Reference | Reference | |||
Metastatic | 2.269 (1.294–3.976) | 0.004 | 2.488 (1.413–4.383) | 0.002 | |
Diameter of primary tumor | |||||
< 8 cm | Reference | ||||
≥ 8 cm | 0.765 (0.434–1.351) | 0.356 | |||
Local therapy | |||||
Surgery | Reference | ||||
Radiotherapy | 1.327 (0.654–2.692) | 0.432 | |||
Surgery + radiotherapy | 1.271 (0.679–2.379) | 0.453 | |||
Time to local therapy | 0.901 (0.733–1.107) | 0.329 | |||
Number of chemotherapy cycles | |||||
< 12 | Reference | Reference | 0.003 | ||
≥ 12 | 0.505 (0.291–0.874) | 0.015 | 0.424 (0.240–0.748) | ||
Frequency of chemotherapy delays | |||||
≥ 25% | Reference | Reference | |||
< 25% | 0.537 (0.270–1.067) | 0.076 | 0.438 (0.217–0.887) | 0.022 | |
Grade 3–4 chemotherapy toxicity | |||||
YES | Reference | 0.610 | |||
NO | 0.595(0.081–4.359) | ||||
Administration of dexrazoxane | |||||
YES | Reference | ||||
NO | 0.938(0.540–1.628) | 0.820 | |||